Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

Acute Respiratory Failure-I

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

Acute Respiratory Failure-III

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...

Acute Pharyngitis

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunologically distinct long COVID after mild acute disease.

Nature immunology·2026

Same author

SARS-CoV-2 vaccines induce a diverse spike-specific CD4+ T cell receptor repertoire in people living with HIV with low CD4 nadirs.

Frontiers in immunology·2025

Same author

Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells.

Cell systems·2025

Same author

CROI 2025: Acute and Postacute COVID-19.

Topics in antiviral medicine·2025

Same author

Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.

Journal of virology·2025

Same author

Intact HIV DNA decays in children with and without complete viral load suppression.

PLoS pathogens·2025

Search research articles

Related Experiment Video

Updated: May 15, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

CROI 2026: Acute and Postacute COVID-19.

Annukka A R Antar¹

¹Johns Hopkins University, Baltimore, MD, USA.

Topics in Antiviral Medicine

|May 13, 2026

Summary

Advances in COVID-19 research include new DNA-encoded monoclonal antibody (DMAb) technology and insights into long COVID. Studies show continued SARS-CoV-2 risks and patient experiences, highlighting the need for better understanding and care.

Area of Science:

Infectious Diseases
Immunology
Virology

Background:

The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted key advancements in understanding COVID-19 and related conditions.
Research explored viral immunity, therapeutics, and the long-term impacts of SARS-CoV-2 infection.

Purpose of the Study:

To summarize critical findings presented at CROI 2026 concerning COVID-19, long COVID, and HIV co-infections.
To evaluate novel therapeutic platforms and assess the ongoing risks and sequelae of SARS-CoV-2 infection.

Main Methods:

First-in-human validation of DNA-encoded monoclonal antibody (DMAb) technology.
Clinical studies on pemivibart in advanced HIV patients.
Pharmacokinetic and safety studies of a novel pan-coronavirus protease inhibitor.

More Related Videos

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

Related Experiment Videos

Last Updated: May 15, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

Observational studies on SARS-CoV-2 infection outcomes and long COVID prevalence.

Main Results:

DMAb technology demonstrated safety and durable antibody production.
Pemivibart was well-tolerated in advanced HIV, inducing neutralizing antibodies.
A new protease inhibitor showed comparable safety and pharmacokinetics in renal and hepatic impairment.
Post-SARS-CoV-2 infection carries risks for new diagnoses and comorbidity worsening; HIV co-infection impacts renal function.
No association found between circulating SARS-CoV-2 antigen and long COVID; patients report clinical stigma.

Conclusions:

Novel DMAb technology shows promise for therapeutic antibody development.
New antiviral agents offer potential treatment options with favorable safety profiles.
Long-term health consequences of SARS-CoV-2 infection, particularly in vulnerable populations like people with HIV, require continued monitoring.
Patient-reported experiences highlight significant psychosocial challenges associated with long COVID.